PMDA– tag –
-
BioCardia’s CardiAMP Autologous Cell Therapy Accelerates Towards Global Approval for Heart Failure
MerlinTrader (BioCardia分析) USA Overview BioCardia's CardiAMP autologous bone marrow cell therapy for cardiovascular disease has achieved significant regulatory milestones. The U.S. FDA confirmed that the ongoing Phase 3 CardiAMP Heart ... -
Japan Nears Approval of BioCardia’s CardiAMP Heart Failure Cell Therapy: PMDA Issues Consultation Record Supporting Regulatory Submission
Longevity.Technology Japan Overview Japan has moved closer to approving BioCardia's CardiAMP cell therapy for ischemic heart failure with reduced ejection fraction (HFrEF). Japan's Pharmaceuticals and Medical Devices Agency (PMDA) issued... -
PMDA’s 2026 Strategy: Streamlining Approvals for Next-Gen Regenerative Medicine, Including iPSCs
独立行政法人 医薬品医療機器総合機構 (PMDA) Japan Overview Japan's Pharmaceuticals and Medical Devices Agency (PMDA) has detailed its 2026 operational strategy for approving novel pharmaceuticals, medical devices, and regenerative medicin... -
Japan’s PMDA Enhances Regulatory Framework for Regenerative Medicine Products Amidst Continuous Updates
独立行政法人 医薬品医療機器総合機構 (PMDA) Japan Overview Japan's Pharmaceuticals and Medical Devices Agency (PMDA) implemented several regulatory updates from May 8-15, 2026, pertaining to pharmaceuticals and regenerative medicine produ...
